SCHEMBL22227918

SCHEMBL22227918

CC(C)(C)[Si](O[C@H]1CC(N2C(=O)c3ccccc3C2=O)C[C@@H]1NC(=O)O)(c1ccccc1)c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ TSHR P16473 2/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ GSK3B P49841 3/20 0.32
▸ CSNK2A1 P68400 3/20 0.32
▸ ALDH1A1 P00352 4/20 0.32
▸ NPSR1 Q6W5P4 2/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.31
▸ ATM Q13315 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ CCR5 P51681 1/20 0.31
▸ SLC6A2 P23975 1/20 0.30
▸ SLC6A4 P31645 1/20 0.30
▸ SLC6A3 Q01959 1/20 0.30
▸ DDB1 Q16531 1/20 0.30
▸ CRBN Q96SW2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22227917 1.00 L3MBTL1 (0.38) L3MBTL1TSHRKMT2AGSK3BCSNK2A1
SCHEMBL30233957 0.86 CPB1 (0.41) TSHRALDH1A1SMN1; SMN2
SCHEMBL28439063 0.86 CPB1 (0.41) TSHRALDH1A1SMN1; SMN2
SCHEMBL20832767 0.83 L3MBTL1 (0.34) L3MBTL1
SCHEMBL33374588 0.82 L3MBTL1 (0.34) L3MBTL1
SCHEMBL22227921 0.82 L3MBTL1 (0.34) L3MBTL1
SCHEMBL20832770 0.82 L3MBTL1 (0.34) L3MBTL1
SCHEMBL22228040 0.77 L3MBTL1 (0.31) L3MBTL1
SCHEMBL22623141 0.77 L3MBTL1 (0.31) L3MBTL1
SCHEMBL18581645 0.77 BACE1 (0.30) NPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230331700-A1 COMPOUND HAVING CYCLIC STRUCTURE DAIICHI SANKYO COMPANY, LIMITED (JP) 2023-10-19 — — US disclosed
US-20200347030-A1 COMPOUND HAVING CYCLIC STRUCTURE DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-11-05 — — US disclosed
EP-3682881-A1 COMPOUND HAVING CYCLIC STRUCTURE DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-07-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200347030-A1 COMPOUND HAVING CYCLIC STRUCTURE H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B L3MBTL1 3800/4885TSHR 1614/4885KMT2A 1805/4885
US-20230331700-A1 COMPOUND HAVING CYCLIC STRUCTURE H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B L3MBTL1 3800/4885TSHR 1614/4885KMT2A 1805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback